DOCSLIB.ORG

Specialty Medications List Harness Health Pharmacy for Participants in the Medical Plan, Specialty Medications Are Prescribed to Treat Complex Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Specialty Medications List Harness Health Pharmacy for Participants in the Medical Plan, Specialty Medications Are Prescribed to Treat Complex Diseases Specialty Medications List Harness Health Pharmacy For participants in the Medical Plan, specialty medications are prescribed to treat complex diseases. Many are available through Harness Health Pharmacy. Participants are limited to 30- day supplies of these specialty drugs. Some medications may require prior authorization. Generics may be available for some medications, and a brand-name version may not be covered under certain plans. This list does not denote coverage or formulary status, merely access. - On the following pages, use Control and F to search the Disease State (such as Asthma or Rheumatology) or the generic name or brand name for any drug. - See the last page for Limited Distribution Drugs available from other pharmacies. If you have questions, call Harness Health Pharmacy at 866-775-5767 (press option 6 for the Specialty staff) weekdays 8 a.m. - 4:30 p.m. (ET). Effective 01/01/2021 Specialty Medications List - Limited Distribution Drugs available through MedImpact Specialty Pharmacy Network AMPYRA EYLEA KUVAN PLEGRIDY TRACLEER APOKYN FERRIPROX KYNAMRO POMALYST TYSABRI ARALAST NP FLOLAN LEMTRADA PROCYSBI TYVASO ARCALYST GATTEX LETAIRIS PURIXAN VELETRI AUBAGIO HETLIOZ MACUGEN RAVICTI VENTAVIS BOSULIF IBRANCE MEKTOVI REMODULIN XALKORI BRAFTOVI ICLUSIG MATULANE REVLIMID XENAZINE BUPHENYL ILARIS METOPIRONE SABRIL ZEMAIRA CAPRELSA IMBRUVICA MYOZYME SIGNIFOR CARBAGLU INCRELEX NAGLAZYME SILIQ CAYSTON INLYTA NORTHERA SUCRAID CERDELGA JUXTAPID OFEV SUTENT CEREZYME KALBITOR OPSUMIT SYMDECO CHOLBAM KALYDECO ORENITRAM ER TECFIDERA CYSTADANE KITABIS PAK ORKAMBI THALOMID Available only through the extended Medimpact Specialty Pharmacy Network (including US Bioservices, Humana Specialty Pharmacy, Kroger Specialty Pharmacy and Accredo.) Call 800-788- 2949. Participants are limited to 30-day supplies of these specialty drugs. Some medications may require prior authorization. Effective: 01/01/2021 Specialty Medications List Harness Health Pharmacy Disease State Generic Name Brand Name Acromegaly LANREOTIDE ACETATE SOMATULINE DEPOT Acromegaly OCTREOTIDE ACETATE BYNFEZIA Acromegaly OCTREOTIDE ACETATE OCTREOTIDE ACETATE Acromegaly OCTREOTIDE ACETATE SANDOSTATIN Acromegaly OCTREOTIDE ACETATE,MI-SPHERES SANDOSTATIN LAR Acromegaly PEGVISOMANT SOMAVERT Alcohol/Opioid Dependency NALTREXONE MICROSPHERES VIVITROL Alpha-1 Antitrypsin Deficiency ALPHA-1-PROTEINASE INHIBITOR GLASSIA Alpha-1 Antitrypsin Deficiency ALPHA-1-PROTEINASE INHIBITOR ARALAST NP Alpha-1 Antitrypsin Deficiency ALPHA-1-PROTEINASE INHIBITOR PROLASTIN C Alpha-1 Antitrypsin Deficiency ALPHA-1-PROTEINASE INHIBITOR ZEMAIRA Anemia DARBEPOETIN ALFA IN POLYSORBAT ARANESP Anemia EPOETIN ALFA EPOGEN Anemia EPOETIN ALFA PROCRIT Anemia EPOETIN ALFA-EPBX RETACRIT Anemia FERRIC CARBOXYMALTOSE INJECTAFER Anemia FERUMOXYTOL FERAHEME Anemia IRON SUCROSE COMPLEX VENOFER Anemia METHOXY PEG-EPOETIN BETA MIRCERA Anticoagulants FONDAPARINUX SODIUM ARIXTRA Anticoagulants FONDAPARINUX SODIUM FONDAPARINUX SODIUM Asthma BENRALIZUMAB FASENRA Asthma MEPOLIZUMAB NUCALA Asthma OMALIZUMAB XOLAIR Asthma RESLIZUMAB CINQAIR Behavioral Health ARIPIPRAZOLE ABILIFY MAINTENA Behavioral Health ARIPIPRAZOLE LAUROXIL ARISTADA Behavioral Health ARIPIPRAZOLE LAUROXIL,SUBMICR. ARISTADA INITIO Behavioral Health ILOPERIDONE FANAPT Behavioral Health OLANZAPINE PAMOATE ZYPREXA RELPREVV Behavioral Health PALIPERIDONE PALMITATE INVEGA SUSTENNA Behavioral Health PALIPERIDONE PALMITATE INVEGA TRINZA Behavioral Health PIMAVANSERIN NUPLAZID Specialty Medications List Harness Health Pharmacy Disease State Generic Name Brand Name Behavioral Health RISPERIDONE PERSERIS Behavioral Health RISPERIDONE MICROSPHERES RISPERDAL CONSTA Botulinum Toxins ABOBOTULINUMTOXINA DYSPORT Botulinum Toxins INCOBOTULINUMTOXINA XEOMIN Botulinum Toxins ONABOTULINUMTOXINA BOTOX Botulinum Toxins RIMABOTULINUMTOXINB MYOBLOC Chronic Pain/Non Opioid Analgesic ZICONOTIDE ACETATE PRIALT Congenital Fibrinogen Deficiency FIBRINOGEN CONCENTRATE (HUMAN) FIBRYGA Cystic Fibrosis AZTREONAM LYSINE CAYSTON Cystic Fibrosis IVACAFTOR KALYDECO Cystic Fibrosis LUMACAFTOR/IVACAFTOR ORKAMBI Cystic Fibrosis TEZACAFTOR/IVACAFTOR SYMDEKO Cystic Fibrosis TOBRAMYCIN/NEBULIZER BETHKIS Cystic Fibrosis TOBRAMYCIN (CAP FOR INHALATION) TOBI PODHALER Cystic Fibrosis TOBRAMYCIN IN 0.225% SOD CHLOR TOBI Cystic Fibrosis TOBRAMYCIN/NEBULIZER KITABIS PAK Cystic Fibrosis TOBRAMYCIN/NEBULIZER TOBRAMYCIN Cystic Fibrosis DORNASE ALFA/ NEBULIZER PULMOZYME Dermatology ACITRETIN ACITRETIN Dermatology ACITRETIN SORIATANE Dermatology ADALIMUMAB HUMIRA PEN PSORIASIS-UVEITIS Dermatology APREMILAST OTEZLA Dermatology BRODALUMAB SILIQ Dermatology DUPILUMAB DUPIXENT Dermatology GUSELKUMAB TREMFYA Dermatology INGENOL MEBUTATE PICATO Dermatology IXEKIZUMAB TALTZ Dermatology SECUKINUMAB COSENTYX Dermatology CERTOLIZUMAB PEGOL CIMZIA Dermatology INFLIXIMAB-DYYB INFLECTRA Dermatology INFLIXIMAB REMICADE Dermatology INFLIXIMAB-ABDA RENFLEXIS Dermatology INFLIXIMAB-AXXQ AVSOLA Specialty Medications List Harness Health Pharmacy Disease State Generic Name Brand Name Dermatology USTEKINUMAB STELARA Dermatology RISANKIZUMAB SKYRIZI Dermatology TILDRAKIZUMAB ILUMYA Dermatology ETANERCEPT ENBREL Dupuytren's Contracture COLLAGENASE CLOSTRIDIUM HIST. XIAFLEX Electrolyte Disorders PATIROMER CALCIUM SORBITEX VELTASSA Electrolyte Disorders SODIUM ZIRCONIUM CYCLOSILICATE LOKELMA Electrolyte Disorders TOLVAPTAN JYNARQUE Electrolyte Disorders TOLVAPTAN SAMSCA Endocrine CINACALCET CINACALCET Endocrine CINACALCET SENSIPAR Endocrine ETELCALCETIDE HYDROCHLORIDE PARSABIV Endocrine HISTRELIN ACETATE SUPPRELIN LA Endocrine HISTRELIN ACETATE VANTAS Endocrine METYRAPONE METOPIRONE Endocrine MIFEPRISTONE KORLYM Endocrine PARATHYROID HORMONE NATPARA Endocrine PASIREOTIDE DIASPARTATE SIGNIFOR Endocrine PASIREOTIDE PAMOATE SIGNIFOR LAR Enzyme Replacement PEGADEMASE BOVINE ADAGEN Enzyme Replacement SACROSIDASE SUCRAID Endometriosis ELAGOLIX ORILISSA Endometriosis NAFARELIN SYNAREL Fertility CETRORELIX ACETATE CETROTIDE Fertility CHORIOGONADOTROPIN ALFA OVIDREL Fertility CHORIONIC GONADOTROPIN, HUMAN CHORIONIC GONADOTROPIN Fertility CHORIONIC GONADOTROPIN, HUMAN NOVAREL Fertility CHORIONIC GONADOTROPIN, HUMAN PREGNYL Fertility FOLLITROPIN ALFA, RECOMBINANT GONAL-F Fertility FOLLITROPIN BETA,RECOMB FOLLISTIM AQ Fertility GANIRELIX ACETATE GANIRELIX ACETATE Fertility MENOTROPINS MENOPUR Fertility MENOTROPINS REPRONEX Specialty Medications List Harness Health Pharmacy Disease State Generic Name Brand Name Fertility UROFOLLITROPIN BRAVELLE Gastroenterology ADALIMUMAB HUMIRA Gastroenterology CERTOLIZUMAB PEGOL CIMZIA Gastroenterology NATALIZUMAB TYSABRI Gastroenterology INFLIXIMAB-DYYB INFLECTRA Gastroenterology INFLIXIMAB REMICADE Gastroenterology INFLIXIMAB-ABDA RENFLEXIS Gastroenterology INFLIXIMAB-AXXQ AVSOLA Gastroenterology TEDUGLUTIDE GATTEX Gastroenterology USTEKINUMAB STELARA Gastroenterology VEDOLIZUMAB ENTYVIO Gastroenterology TOFACITINIB CITRATE XELJANZ Genetics MIGLUSTAT MIGLUSTAT Genetics MIGLUSTAT ZAVESCA Gout PEGLOTICASE KRYSTEXXA Growth Hormone and Related Disorders MECASERMIN INCRELEX Growth Hormone and Related Disorders SOMATROPIN GENOTROPIN Growth Hormone and Related Disorders SOMATROPIN HUMATROPE Growth Hormone and Related Disorders SOMATROPIN NORDITROPIN Growth Hormone and Related Disorders SOMATROPIN NORDITROPIN NORDIFLEX Growth Hormone and Related Disorders SOMATROPIN NUTROPIN AQ NUSPIN Growth Hormone and Related Disorders SOMATROPIN NUTROPIN AQ Growth Hormone and Related Disorders SOMATROPIN NUTROPIN Growth Hormone and Related Disorders SOMATROPIN OMNITROPE Growth Hormone and Related Disorders SOMATROPIN SAIZEN Growth Hormone and Related Disorders SOMATROPIN SAIZEN-SAIZENPREP Growth Hormone and Related Disorders SOMATROPIN SEROSTIM Growth Hormone and Related Disorders SOMATROPIN TEV-TROPIN Growth Hormone and Related Disorders SOMATROPIN ZOMACTON Growth Hormone and Related Disorders SOMATROPIN ZORBTIVE Heavy Metal Toxicity PENICILLAMINE CUPRIMINE Heavy Metal Toxicity PENICILLAMINE DEPEN Heavy Metal Toxicity TRIENTINE SYPRINE Specialty Medications List Harness Health Pharmacy Disease State Generic Name Brand Name Heavy Metal Toxicity TRIENTINE HCL TRIENTINE HCL Hematopoietics PLERIXAFOR MOZOBIL Hemophilia & Bleeding Disorders ANTIHEM.FVIII,SIN-CHN,B-DM TRU AFSTYLA Hemophilia & Bleeding Disorders ANTIHEMO.FVIII,FULL LENGTH PEG ADYNOVATE Hemophilia & Bleeding Disorders ANTIHEMOPH.FVIII REC,FC FUSION ELOCTATE Hemophilia & Bleeding Disorders ANTIHEMOPH.FVIII,B-DOM TRUNCAT NOVOEIGHT Hemophilia & Bleeding Disorders ANTIHEMOPH.FVIII,B-DOMAIN DEL XYNTHA Hemophilia & Bleeding Disorders ANTIHEMOPH.FVIII,FULL LENGTH ADVATE Hemophilia & Bleeding Disorders ANTIHEMOPH.FVIII,FULL LENGTH KOGENATE FS Hemophilia & Bleeding Disorders ANTIHEMOPH.FVIII,HEK B-DELETE NUWIQ Hemophilia & Bleeding Disorders ANTIHEMOPHIL.FVIII,FULL LENGTH ADVATE Hemophilia & Bleeding Disorders ANTIHEMOPHIL.FVIII,FULL LENGTH HELIXATE FS Hemophilia & Bleeding Disorders ANTIHEMOPHIL.FVIII,FULL LENGTH KOVALTRY Hemophilia & Bleeding Disorders ANTIHEMOPHIL.FVIII REC,B-DOM DELET PEG-AUCL JIVI Hemophilia & Bleeding Disorders ANTIHEMOPHILIC FACTOR, HUM REC RECOMBINATE Hemophilia & Bleeding Disorders ANTIHEMOPHILIC FACTOR, HUMAN HEMOFIL M Hemophilia & Bleeding Disorders ANTIHEMOPHILIC FACTOR, HUMAN KOATE Hemophilia & Bleeding Disorders ANTIHEMOPHILIC FACTOR, HUMAN MONOCLATE-P Hemophilia & Bleeding Disorders ANTIHEMOPHILIC FACTOR/VWF ALPHANATE Hemophilia & Bleeding Disorders ANTIHEMOPHILIC FACTOR/VWF HUMATE-P Hemophilia & Bleeding Disorders ANTIHEMOPHILIC FACTOR/VWF
Load more

Recommended publications
  • September 11, 2018 DUR Minutes
    Maine Department of Health and Human Services PAUL R. LEPAGE MaineCare Services BETHANY L. HAMM GOVERNOR Pharmacy Unit ACTING COMMISSIONER 11 State House Station Augusta, Maine 04333-0011 TO: Maine Drug Utilization Review Board DATE: 9/14/2018 RE: Maine DUR Board Meeting minutes from September 11, 2018 ATTENDANCE PRESENT ABSENT EXCUSED Linda Glass, MD X Lisa Wendler, Pharm. D., Clinical Pharmacy Specialist, X Maine Medical CTR Mike Antoniello, MD X Kathleen Polonchek, MD X Kenneth McCall, PharmD X Steve Diaz, MD X Erin Ackley, PharmD. X Corinn Martineau, PharmD. X Non –Voting Mike Ouellette, R.Ph., Change Healthcare X Jeffery Barkin, MD, Change Healthcare X Christopher Pezzullo, State Health Officer DHHS, DO X Jill Kingsbury, MaineCare Pharmacy Director X Guests of the Board: Ed Bosshart, PharmD, Jeff Caulfield, Lead Epidemiologist for Viral Infections from CDC: Discussed HCV treatment. CALL TO ORDER: 5:30PM Jill Kingsbury called the meeting to order at 5:30 PM. PUBLIC COMMENTS Robert Mead from Pfizer: Highlighted the attributes of Retacrit. Jane Guo from Otsuka: Highlighted the attributes of Jynarque. OLD BUSINESS DUR MINUTES The June DUR meeting minutes were accepted as written. MAINECARE UPDATE No update at this time. NEW BUSINESS INTRODUCTION: USE OF CHRONIC TRIPTANS The use of triptans has become standard of care for the treatment of acute migraine headaches, given their effectiveness, safety and tolerability. However, like many medications used to treat migraine, overuse renders them less effective. Additionally, rebound headaches from triptan overuse is common. For patients who experience frequent headaches, or whose headaches are long lasting or chronic, use of headache prophylactic medications are recommended by several medical associations, including the American Headache Society and the American Academy of Neurology.
    [Show full text]
  • List of Approved Ndas for Biological Products That Were Deemed to Be Blas on March 23, 2020
    List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020 On March 23, 2020, an approved application for a biological product under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) was deemed to be a license for the biological product under section 351 of the Public Health Service Act (PHS Act) (see section 7002(e)(4)(A) of the Biologics Price Competition and Innovation Act of 2009). To enhance transparency and facilitate planning for the March 23, 2020, transition date, FDA compiled a preliminary list of approved applications for biological products under the FD&C Act that were listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) and that would be affected by this transition provision. FDA posted this list on the FDA website in December 2018, and periodically updated this list before the March 23, 2020, transition date. The September 2019 update to this preliminary list added certain administratively closed applications related to approved applications for biological products that were on the December 2018 version of this list. The January 2020 update to the preliminary list reflected a change to the definition of “biological product” made by the Further Consolidated Appropriations Act, 2020, which was enacted on December 20, 2019. Section 605 of this Act further amended the definition of a “biological product” in section 351(i) of the PHS Act to remove the parenthetical “(except any chemically synthesized polypeptide)” from the statutory category of “protein.” FDA has provided below a list of each approved application for a biological product under the FD&C Act that was deemed to be a license (i.e., an approved biologics license application (BLA)) for the biological product on March 23, 2020.
    [Show full text]
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,993,812 Tsoukas Et Al
    USOO5993812A United States Patent (19) 11 Patent Number: 5,993,812 TSOukas et al. (45) Date of Patent: Nov.30, 1999 54 METHOD OF DELAYING THE Brunkhorst et al., Infection 18:28-32, 1990. PROGRESSION OF AN INFECTION WITH Coyle et al., Changes in the Lymphocyte Count and Lym THE HUMAN IMMUNODEFICIENCY VIRUS phocyte Subsets After Splenectomy in Human Immunode ficiency Virus Infection, Letters and Correspondence, pp. 75 Inventors: Christos M. Tsoukas, Montreal; Barry 144-146. Michael Woloski, Winnipeg, both of DeSimone et al., Immunopharma. and Immunotoxic., Canada 13:447-458, 1991. Gringeri et al., British Journal of Haemotology, 80:337-340, 73 Assignee: Cangene Corporation, Winnipeg, 1992. Canada Gingör et al., Eur. J. Pediatr., 152:650–654, 1993. Mofenson and Moye, Pediatric Research, 33:80-S89, 1993. 21 Appl. No.: 08/835,400 Mofenson et al., Journal of Acquired Immune Deficiency 22 Filed: Apr. 7, 1997 Syndrome, 6:1103-1113, 1993. Schrappe-Bächer et al., Vox Sang, 59:3-14, 1990. Related U.S. Application Data Shearer et al., Ann. N.Y. Acad. Sci., pp. 35-51. Wagner et al., Arch. of Disease in Childhood., 63 Continuation-in-part of application No. 08/713,765, Sep. 13, 67:1267-1271, 1992. 1996, abandoned. Watson, et al., “Recombinant DNA”, Scientific American 60 Provisional application No. 60/003,756, Sep. 14, 1995. Books, Chapter 25. 51) Int. Cl. ............................ A61K 39/395; CO7K 1/00 Okesenhendeler, et al., “Anti-RH immunoglobulin therapy 52 U.S. Cl. ................... 424/130.1; 530/350, 530/388.7; for human immunodeficiency virus-related immune throm 424/142.1; 424/141.1; 424/153.1 bocytopenic purpura’, Blood, 71 (5) 1499-502.
    [Show full text]
  • TEXAS MEDICAID Clinical Edit Prior Authorization Epoetin Alfa (PROCRIT)
    TEXAS MEDICAID Clinical Edit Prior Authorization epoetin alfa (PROCRIT) STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING Date: Prescriber First & Last Name: Patient First & Last Name: Prescriber NPI: Patient Address: Prescriber Address: Patient ID: Prescriber Phone: Patient Date of Birth: Prescriber Fax: STEP 2: MEDICATION INFORMATION Medication Requested (Name): Quantity Requested: Dose Requested: Dosing Instructions: Patient’s Primary Diagnosis: ____________________________________ ICD 10 Code: __________ Please indicate ONE (1) of the following: OR STAR / STAR KIDS client (Go to Step 3 - PDL PA Criteria Applies) OR CHIP / PERINATE client (Go to Step 4) STEP 3: PDL PRIOR AUTHORIZATION CRITERIA FOR NON-PREFERRED PRODUCT 1. Has the client failed a 30-day treatment trial with at least 1 preferred agent in the last 180 days? Yes (Go to Step 4 Question 1) No (Go to #2) 2. Is there a documented allergy or contraindication to preferred agents in this class? Yes (Go to Step 4 Question 1) No (Go to #3) 3. Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions? Yes (Go to Step 4 Question 1) No (Deny) Rev. 11/18/2020 Page 1 of 3 Version 1.5 STEP 4: CLINICAL PRIOR AUTHORIZATION CRITERIA 1. Does the client have a diagnosis of chronic renal failure in the last 730 days? Yes (Go to #7) No (Go to #2) 2. Does the client have a diagnosis of cancer in the last 730 days? Yes (Go to #3) No (Go to #5) 3. Does the client have a history of an antineoplastic agent in the last 30 days? Examples of antineoplastic
    [Show full text]
  • Tavalisse™ (Fostamatinib) (Oral) Document Number: IC-0361 Last Review Date: 02/02/2021 Date of Origin: 06/01/2018 Dates Reviewed: 06/2018, 02/2019, 02/2020, 02/2021
    Tavalisse™ (fostamatinib) (Oral) Document Number: IC-0361 Last Review Date: 02/02/2021 Date of Origin: 06/01/2018 Dates Reviewed: 06/2018, 02/2019, 02/2020, 02/2021 I. Length of Authorization Coverage is provided for six months and may be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: 100 mg tablets – 2 tablets per day 150 mg tablets – 2 tablets per day B. Max Units (per dose and over time) [HCPCS Unit]: 300 mg daily III. Initial Approval Criteria 1,2 Coverage is provided in the following conditions: Patient is at least 18 years of age; AND Universal Criteria 1 Patient is not receiving a thrombopoietin receptor agonist or mimetic (e.g., romiplostim, eltrombopag, lusutrombopag, avatrombopag, etc.); AND Laboratory values are current (i.e., drawn within the previous 28 days); AND Fostamatinib is not being used to attempt to normalize platelet count; AND Patient will avoid concomitant therapy with any of the following: o Coadministration with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ketoconazole, etc.), or if therapy is unavoidable, the patient will be monitored closely for adverse reaction and/or dose modifications will be implemented; AND o Coadministration with strong CYP3A inducers (e.g., rifampin, carbamazepine, St. John’s Wort, etc.); AND Chronic Immune Thrombocytopenia (ITP) † 1-5 Patient has had persistent/chronic ITP for at least 3 months; AND Proprietary & Confidential © 2021 Magellan Health, Inc. Patient has previously failed any of the following treatments for ITP: Patient has failed previous therapy with corticosteroids (i.e., patient had no response to at least a 3-month trial or is corticosteroid-dependent); OR Patient has failed previous therapy with immunoglobulins; OR Patient has had a splenectomy; OR Patient has failed previous therapy with a thrombopoietin receptor agonist; AND The patient is at increased risk for bleeding as indicated by platelet count of less than 30 × 109/L (30,000/mm³) † FDA Approved Indication(s) IV.
    [Show full text]
  • VIDEX (Didanosine) Chewable/Dispersible Buffered Tablets
    Rx only VIDEXâ (didanosine) â VIDEX (didanosine) Chewable/Dispersible Buffered Tablets â VIDEX (didanosine) Buffered Powder for Oral Solution â VIDEX (didanosine) Pediatric Powder for Oral Solution (Patient Information Leaflet Included) WARNING FATAL AND NONFATAL PANCREATITIS HAVE OCCURRED DURING THERAPY WITH VIDEX USED ALONE OR IN COMBINATION REGIMENS IN BOTH TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS, REGARDLESS OF DEGREE OF IMMUNOSUPPRESSION. VIDEX SHOULD BE SUSPENDED IN PATIENTS WITH SUSPECTED PANCREATITIS AND DISCONTINUED IN PATIENTS WITH CONFIRMED PANCREATITIS (SEE WARNINGS). LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS, INCLUDING FATAL CASES, HAVE BEEN REPORTED WITH THE USE OF NUCLEOSIDE ANALOGUES ALONE OR IN COMBINATION, INCLUDING DIDANOSINE AND OTHER ANTIRETROVIRALS. FATAL LACTIC ACIDOSIS HAS BEEN REPORTED IN PREGNANT WOMEN WHO RECEIVED THE COMBINATION OF DIDANOSINE AND STAVUDINE WITH OTHER ANTIRETROVIRAL AGENTS. THE COMBINATION OF DIDANOSINE AND STAVUDINE SHOULD BE USED WITH CAUTION DURING PREGNANCY AND IS RECOMMENDED ONLY IF THE POTENTIAL BENEFIT CLEARLY OUTWEIGHS THE POTENTIAL RISK. (SEE WARNINGS AND PRECAUTIONS: PREGNANCY.) Page 4 of 39 DESCRIPTION â VIDEX (didanosine) is a brand name for didanosine (ddI), a synthetic purine nucleoside analogue active against the Human Immunodeficiency Virus (HIV). VIDEX Chewable/Dispersible Buffered Tablets are available for oral administration in strengths of 25, 50, 100, 150, and 200 mg of didanosine. Each tablet is buffered with calcium carbonate and magnesium hydroxide. VIDEX tablets also contain aspartame, sorbitol, microcrystalline cellulose, polyplasdone, mandarin-orange flavor, and magnesium stearate. VIDEX Buffered Powder for Oral Solution is supplied for oral administration in single- dose packets containing 100, 167, or 250 mg of didanosine. Packets of each product strength also contain a citrate-phosphate buffer (composed of dibasic sodium phosphate, sodium citrate, and citric acid) and sucrose.
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • Horizon Therapeutics Public Annual Report 2020
    Horizon Therapeutics Public Annual Report 2020 Form 10-K (NASDAQ:HZNP) Published: February 26th, 2020 PDF generated by stocklight.com octb inte UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35238 HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY (Exact name of Registrant as specified in its charter) Ireland Not Applicable (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Connaught House, 1st Floor 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland Not Applicable (Address of principal executive offices) (Zip Code) 011 353 1 772 2100 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Ordinary shares, nominal value $0.0001 per share HZNP The Nasdaq Global Select Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐. Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Fee-For-Service Preferred Drug List
    Prescription Drug Program Apple Health Medicaid: Fee-for-Service Preferred Drug List What is new in this version of the preferred drug list? Effective for dates of service on and after January 1, 2018, the Health Care Authority will make the following changes: Unless otherwise indicated in the drug class information, the authorization criteria is that the client must have tried and failed, or is intolerant to, at least two or more preferred drugs within the drug class unless contraindicated, not clinically appropriate, or only one drug is preferred. Drugs may have criteria that go beyond these basic criteria. Drug classes that are subject to the Therapeutic Interchange Program (TIP), are noted in the drug class information. For more information on TIP, see Theraputic Interchange Program in the Prescription Drug Program Medicaid Billing Guide. Drug Class Drug Name Change ACE Inhibitors Univasc Removed, no longer manufactured Galantamine Removed, no longer manufactured Alzheimer’s Drugs Aricept ODT Removed, no longer manufactured Exelon solution Removed, no longer manufactured Adrenaclick Non-Preferred, PA required Anaphylaxis Agents: Adrenalin Non-Preferred, PA required Epinephrine, Self Epinephrine Non-Preferred, PA required Injectable (new drug class) Epinephrine (Mylan only) Preferred Epipen 2-Pak/ JR 2-Pak Non-Preferred, PA required (Rev. 12/28/2017)(Eff. 1/1/2018) – 1 – Apple Health Medicaid PDL Prescription Drug Program Renamed drug class “Anticoagulants: Anticoagulants Entire class Factor XA and Thrombin Inhibitors.” Anticoagulants:
    [Show full text]
  • Blood Modifier Agents Policy #: Rx.01.208
    Pharmacy Policy Bulletin Title: Blood Modifier Agents Policy #: Rx.01.208 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some medications may be subject to precertification, age, quantity, or formulary restrictions (ie limits on non-preferred drugs). Individual member benefits must be verified. This pharmacy policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety, or FDA approval may have changed. This Pharmacy Policy will be regularly updated as scientific and medical literature becomes available. This information may include new FDA-approved indications, withdrawals, or other FDA alerts. This type of information is relevant not only when considering whether this policy should be updated, but also when applying it to current requests for coverage. Members are advised to use participating pharmacies in order to receive the highest level of benefits. Intent: The intent of this policy is to communicate the medical necessity criteria for eltrombopag olamine (Promacta®), fostamatinib disodium (Tavalisse™), avatrombopag (Doptelet®), lusutrombopag (Mulpleta®) as provided under the member's prescription drug benefit. Description: Idiopathic thrombocytopenia purpura (ITP): ITP is an immune disorder in which the blood doesn't clot normally. ITP can cause excessive bruising and bleeding and can be characterized as an unusually low level of platelets, or thrombocytes, in the blood results in ITP. Thrombocytopenia in patients with hepatitis C: Thrombocytopenia can occur in patients with chronic hepatitis C virus (HCV) infection.
    [Show full text]
  • UWHC Guidelines for the Use of Darbepoetin and Epoetin
    Use of Darbepoetin and Epoetin in Non-Nephrology Patients – Adult/Pediatric – Inpatient/Ambulatory Clinical Practice Guideline Table of Contents Executive Summary ......................................................................................... 3 Scope ............................................................................................................. 7 Methodology ................................................................................................... 7 Definitions (optional): ...................................................................................... 8 Introduction.................................................................................................... 8 Recommendations........................................................................................... 9 UW Health Implementation............................................................................ 19 References ................................................................................................... 19 Note: Active Table of Contents Click to follow link CPG Contact for Changes: Name: Philip Trapskin, PharmD, BCPS, Manager, DPP Phone Number: 608-263-1328 Email address: [email protected] CPG Contact for Content: Name: Jason Bergsbaken, PharmD Phone Number: 608-265-0341 Email address: [email protected] Copyright © 2015 University of Wisconsin Hospitals and Clinics Authority Contact: [email protected] Vermeulen, [email protected] Last Revised: 07/2015 Guideline Authors: Jason Bergsbaken, PharmD Coordinating
    [Show full text]